These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37146620)

  • 21. Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.
    Inoue K; Masuda N; Iwata H; Takahashi M; Ito Y; Miyoshi Y; Nakayama T; Mukai H; van der Walt JS; Mori J; Sakaguchi S; Kawaguchi T; Tanizawa Y; Llombart-Cussac A; Sledge GW; Toi M
    Breast Cancer; 2021 Sep; 28(5):1038-1050. PubMed ID: 33797023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer.
    Royce M; Osgood C; Mulkey F; Bloomquist E; Pierce WF; Roy A; Kalavar S; Ghosh S; Philip R; Rizvi F; Mixter BD; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L
    J Clin Oncol; 2022 Apr; 40(11):1155-1162. PubMed ID: 35084948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
    Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
    Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
    Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
    BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
    Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Conte P; Lu Y; Barriga S; Hurt K; Frenzel M; Johnston S; Llombart-Cussac A
    JAMA Oncol; 2020 Jan; 6(1):116-124. PubMed ID: 31563959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.
    Patnaik A; Rosen LS; Tolaney SM; Tolcher AW; Goldman JW; Gandhi L; Papadopoulos KP; Beeram M; Rasco DW; Hilton JF; Nasir A; Beckmann RP; Schade AE; Fulford AD; Nguyen TS; Martinez R; Kulanthaivel P; Li LQ; Frenzel M; Cronier DM; Chan EM; Flaherty KT; Wen PY; Shapiro GI
    Cancer Discov; 2016 Jul; 6(7):740-53. PubMed ID: 27217383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abemaciclib-Associated Status Epilepticus.
    Raziq FI
    Am J Ther; 2022 Nov-Dec 01; 29(6):e772-e774. PubMed ID: 32496440
    [No Abstract]   [Full Text] [Related]  

  • 28. Abemaciclib (Verzenio)--a third CDK 4/6 inhibitor for breast cancer.
    Med Lett Drugs Ther; 2017 Nov; 59(1533):185-186. PubMed ID: 29125595
    [No Abstract]   [Full Text] [Related]  

  • 29. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
    Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
    Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib.
    Tarantino P; Jin Q; Mittendorf EA; King TA; Curigliano G; Tolaney SM
    Ann Oncol; 2022 Aug; 33(8):845-847. PubMed ID: 35525374
    [No Abstract]   [Full Text] [Related]  

  • 31. Coronary Plaque Erosion after Abemaciclib Treatment Onset: An Unknown Side Effect?
    Vera A; Rivero F; Salamanca J; Alvarado-Casas T; Alfonso F
    Thromb Haemost; 2021 Jul; 121(7):976-978. PubMed ID: 33260247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Orozco Leal G; Armstrong N; Kernohan A; Ahmadu C; Coughlan D; McDermott K; Duffy S; O'Meara S; Robinson T; Vale L; Kleijnen J
    Pharmacoeconomics; 2023 Jul; 41(7):741-750. PubMed ID: 36952138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Development of CDK4 & 6 Inhibitor Abemaciclib in Breast Cancer].
    Masuda N; Saji S; Kawaguchi T; Chen Y; Ohno S
    Gan To Kagaku Ryoho; 2021 Dec; 48(12):1475-1483. PubMed ID: 34911915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan.
    Chen Y; Noma S; Taguchi Y; Takahashi M; Tsurutani J; Mori S; Sakaguchi S; Asou H; Tomii K
    Breast Cancer; 2021 May; 28(3):710-719. PubMed ID: 33453015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of advanced HR+/HER2- breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib.
    Bøttcher TM; Cold S; Jensen AB
    Acta Oncol; 2019 Feb; 58(2):147-153. PubMed ID: 30375908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer.
    O'Brien N; Conklin D; Beckmann R; Luo T; Chau K; Thomas J; Mc Nulty A; Marchal C; Kalous O; von Euw E; Hurvitz S; Mockbee C; Slamon DJ
    Mol Cancer Ther; 2018 May; 17(5):897-907. PubMed ID: 29483214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
    Toi M; Inoue K; Masuda N; Iwata H; Sohn J; Hae Park I; Im SA; Chen SC; Enatsu S; Turner PK; André VAM; Hardebeck MC; Sakaguchi S; Goetz MP; Sledge GW
    Cancer Sci; 2021 Jun; 112(6):2381-2392. PubMed ID: 33686753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant abemaciclib for high-risk breast cancer: the story continues.
    Spring L; Matikas A; Bardia A; Foukakis T
    Ann Oncol; 2021 Dec; 32(12):1457-1459. PubMed ID: 34815015
    [No Abstract]   [Full Text] [Related]  

  • 39. Abemaciclib Shows Promise for Early Breast Cancer.
    Cancer Discov; 2017 Feb; 7(2):119-120. PubMed ID: 27986713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In brief: A new indication for abemaciclib (Verzenio).
    Med Lett Drugs Ther; 2023 Apr; 65(1673):e62-e63. PubMed ID: 37020345
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.